InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.735 0.03 (4.26%)+
Announcement
Release
29 Apr 2026 10:15AM
Price at Release
$0.705
Full Release
download
Summary
Starpharma Holdings Limited announced its quarterly activities and Appendix 4C cash flow report for the quarter ending 31 March 2026. The company confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 clinical study, which is on track to begin in the second half of 2026. Starpharma advanced strategic partnerships through engagements at key conferences and published collaborative research with Genentech, demonstrating the potential of its DEP® platform. The company maintained a cash balance of $14.1 million with net operating cash outflows of $3.9 million. Commercial activities for Viraleze™ showed significant growth in web sales. Starpharma continues to prepare for its clinical study and explore new therapeutic opportunities using its dendrimer technology.
Key Points
  • FDA alignment confirmed for DEP® HER2 first-in-human phase 1 clinical study.
  • Strategic partnerships and platform validation advanced through engagements at JP Morgan and BIO-Europe.
  • Publication of research collaboration with Genentech in the Journal of Pharmaceutical Sciences.
  • Preparation for first-in-human phase 1 study of DEP® HER2 radiotherapeutic candidate.
  • Starpharma's cash balance was $14.1 million as of 31 March 2026.
  • Net operating cash outflows for the quarter were $3.9 million.
  • Continued commercial activities for Viraleze™ with an increase in web sales.
  • Presented at the Ignite Investment Summit in Hong Kong.
  • Estimated quarters of funding available is 3.7 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.